Joey Azofeifa, Arpeggio Biosciences CEO

Tiny tran­scrip­tome biotech se­cures Se­ries A to ramp up au­to­mat­ed R&D ef­forts in race to­ward clin­ic

A Col­orado com­pa­ny is look­ing to re-up its ef­forts to ex­pand and go in­to the clin­ic, and thanks to some fresh cash from an in­vest­ing group, the biotech is head­ed in that di­rec­tion.

Arpeg­gio Bio­sciences an­nounced Wednes­day morn­ing that it suc­cess­ful­ly raised $17 mil­lion in a Se­ries A round, two years af­ter a $3.2 mil­lion seed round and four years af­ter be­ing ini­tial­ly found­ed. CEO and co-founder Joey Azofeifa tells End­points News that the fund­ing will ini­tial­ly go to pipeline de­vel­op­ment and au­tomat­ing its com­pound-screen­ing ef­forts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.